Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers

Healthy Clinical Trial

Official title:

A Phase 1 Open-Label, Non-Randomized, Single-Dose, Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smoker Versus Non-Smoker Healthy Adult Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03516305
• Other study ID #: EPK-002
• Status: Completed
• Phase: Phase 1
• Start date: April 6, 2018
• Est. completion date: August 1, 2018

Study information

• Verified date: April 2022
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized, single dose, pharmacokinetic study in 36 healthy adult male and female volunteers, including 18 smokers and 18 non-smokers. All subjects will be administered a single inhaled dose of Staccato alprazolam 1 mg via hand-held inhaler. Blood samples will be drawn for pharmacokinetic analysis. Eligible subjects are admitted to Phase 1 unit for up to 48 hours. Subjects will receive a post-study safety phone call 14 days(± 2 days) after dosing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 1, 2018
• Est. primary completion date: August 1, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 50 Years

Eligibility

Inclusion Criteria:

• These inclusion criteria (items 1-8) apply to all subjects, smokers and non-smokers:

I. Healthy male and female subjects between the ages of21 to 50 years, inclusive.

2. Body mass index (BMI) >/= 18 and </= 30 kg/m2, inclusive.

3. Able to speak, read, and understand English and are willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures.

4. Willing and able to be confined to a clinical research facility for up to 48 hours (including 2 nights) and comply with the study schedule and study requirements.

5. Normal spirometry at screening as demonstrated by FEVI +/- 80% of predicted and FVC +/- 80% of predicted.

6. Adequate veins, as assessed by the Investigator or Investigator's designee, that are suitable for the required number and frequency of PK blood draws in this study.

7. In otherwise good general health as determined by a complete medical history, physical examination, 12-lead electrocardiogram (ECG), blood chemistry profile, hematology, serology (HIV-l/2Ab, HBsAg, HCV Ab), and urinalysis at screening.

8. Female participants (if of child-bearing potential and sexually active) and male participants (if sexually active with a partner of child-bearing potential) who agree to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study.

Smokers must meet the following inclusion criteria (items 9-10):

9. A history of smoking> 15 cigarettes/day currently and for at least the last 2 years.

10. Serum cotinine +/-500 ng/mL at Screening Visit I.

Nonsmokers must meet the following inclusion criteria (items 11-12):

11. A history of never smoking> 5 cigarettes/day and not smoking at all for at least the last 2 years prior to Visit I.

12. Serum cotinine :o 40 ng/mL at Screening Visit I and a negative urine cotinine test at Visit 2 Day-I.

Exclusion Criteria:

1. Treatment with an investigational drug within 30 days ( or within 5 half-lives of the investigational drug, if>30 days) prior to Visit I.

2. Significant hepatic, renal, gastroenterologic, cardiovascular endocrine, neurologic (including history of seizures or stroke), or hematologic disease.

3. Any acute illness in the 5 days prior to Visit 2.

4. Upper respiratory tract infection within 6 weeks of Visit 2 or bronchitis or pneumonia within 6 months of Visit 2.

5. Use of a bronchodilator for the treatment of wheezing within 12 months of Visit I.

6. Diagnosis of an active or chronic pulmonary disease.

7. Lung resection or other pulmonary surgery within 12 months of Visit I.

8. A history of allergy or intolerance to alprazolam.

9. Use of any other prescription or nonprescription medication--with the exception of acetaminophen, ibuprofen or ongoing doses of oral contraceptives or vitamins--within 5 days prior to study drug administration.

10. A history within the past 2 years of drug or alcohol dependence or abuse.

11. Positive test for alcohol or a positive urine screen for drugs of abuse at screening

12. A positive HIV test.

13. Breastfeeding or a positive pregnancy test at screening (female subjects).

14. Clinically significant ECG abnormality.

15. Hypotension or hypertension, at screening or baseline.

16. Poor veins in the opinion of the Investigator or the Investigator's designee such that the participant is judged to likely have difficult venipuncture during the study.

17. Any other disease or condition, by history, physical examination, or laboratory abnormalities that in the investigator's opinion, would present undue risk to the subject, or may confound the interpretation of study results.

18. Participation in another clinical trial within 2 months of the beginning of the present study, or blood donation or comparable blood loss (>350mL) within 2 months before the present study.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Staccato Alprazolam 1 mg
alprazolam I mg administered via the Staccato hand-held inhaler device system.

Locations

Country	Name	City	State
United States	Clinilabs Research Unit	Eatontown	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Engage Therapeutics, Inc.	Clinilabs, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics (PK) : Maximum observer drug concentration (Cmax)	Cmax of alprazolam in smokers compared to non-smokers	Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.
Primary	PK: Area under the concentration versus time curve (AUC)from Zero to Infinity (AUC[0-8]	AUC[0-8] of alprazolam in smokers compared to non-smokers	Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.
Secondary	PK;: time after administration of a drug when the maximum plasma concentration is reached (Tmax)	Tmax of alprazolam in smokers compared to non-smokers	Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.
Secondary	PK: half-life (t1/2)	t1/2 of alprazolam in smokers compared to non-smokers	Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.